about
Characteristic features of cytotoxic activity of flavonoids on human cervical cancer cellsCytotoxicity of dietary flavonoids on different human cancer typesA retrospective of recombinant P2Y receptor subtypes and their pharmacology.Involvement of P2Y receptors in the differentiation of haematopoietic cells.Estonian folk traditional experiences on natural anticancer remedies: from past to the future.Nongenomic effects of 17beta-estradiol--diversity of membrane binding sites.Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptorNeuronal and glial cell lines as model systems for studying P2Y receptor pharmacology.Chemotherapy and dietary phytochemical agents.Site-specific anticancer effects of dietary flavonoid quercetin.Dependence of DPPH radical scavenging activity of dietary flavonoid quercetin on reaction environment.Role of flavonoids in future anticancer therapy by eliminating the cancer stem cells.Ace I/D polymorphism is associated with habitual physical activity in pubertal boys.Chemomodulating Effects of Flavonoids in Human Leukemia Cells.Multi-Target Cytotoxic Actions of Flavonoids in Blood Cancer Cells.Molecular mechanisms underlying chemopreventive potential of curcumin: Current challenges and future perspectives.Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids.Potentiation of luteolin cytotoxicity by flavonols fisetin and quercetin in human chronic lymphocytic leukemia cell lines.Molecular mechanisms of action of quercetin in cancer: recent advances.A new lignan glycoside from the aerial parts and cytotoxic investigation of Uvaria rufa.The Val158Met polymorphism in COMT gene and cancer risk: role of endogenous and exogenous catechols.Mechanistic insight into carnosol-mediated pharmacological effects: Recent trends and advancements.Pharmacological characterisation of pyrimidinoceptor responses in NG108-15 cells.Pyrimidinoceptor potentiation by ATP in NG108-15 cells.Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids.'Strain effect' descriptors for ATP and ADP derivatives with modified phosphate groups.The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis.Epidemiological Evidences on Dietary Flavonoids and Breast Cancer Risk: A Narrative ReviewAnalysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.Intake of Individual Flavonoids and Risk of Carcinogenesis: Overview of Epidemiological Evidence.Cytotoxic action of methylquercetins in human lung adenocarcinoma cells.Therapeutic charm of quercetin and its derivatives: a review of research and patents.Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy.Genetic assessment following increased nuchal translucency and normal karyotype.Current epidemiological knowledge about the role of flavonoids in prostate carcinogenesis.Evaluation of the 124-plex SNP typing microarray for forensic testing.Distinctive Genetic Profile With IDH1, TP53, and MLH1 Mutations in a Radiation-Induced Anaplastic Astrocytoma.Adenosine-derived non-phosphate antagonists for P2Y(1) purinoceptors.Only pyrimidinoceptors are functionally expressed in mouse neuroblastoma cell lines.Suppression of Taxanes Cytotoxicity by Citrus Flavonoid Hesperetin in PPC-1 Human Prostate Cancer Cells
P50
Q26853532-5A0393D2-1254-4652-9096-DE8F358ECFFEQ27012643-C08213D7-8BCC-4DD9-89A7-425EDC54E763Q34465257-C22833AC-1C4C-432B-BCCE-BC68CC43700BQ35093125-DA913071-F28D-49FD-953D-E996D1B71D2DQ35185728-3172FB9C-9BA3-4585-B7A3-E028B4A8A0E1Q35774360-E920264D-25D4-489C-BD3D-43A1B3E92E47Q36108243-FA923059-DA6F-49B0-818B-3F0227B1D68EQ36218849-9545418D-E221-4672-9F0E-776A6C409C47Q36516033-B18E2878-2AA9-4952-8E17-8253ED7A45F4Q38174655-61BD0B74-5107-4D8F-9ED7-A7F2FCEBFBBFQ38222663-27B97672-CFC6-491B-9F93-9F073697982EQ38272040-07F22F11-90D0-40A2-BAD6-221F8F83E6C4Q38425142-D1D02CC9-10F9-4DB7-B9F0-537C351A8ACCQ38489452-FD64BC1F-91B6-43CE-A5F2-078882848324Q38545186-34FB0970-4711-4EA5-97C8-3F32FE9F6572Q38733520-3DA8D895-C44A-4AEF-95A0-7D004F5D534DQ38739970-6443A8B5-36CE-4B0A-A740-A65363DF611EQ38834734-0AE3393B-3E46-459E-9D91-1CC580F24B47Q38905686-B37FF952-8E2C-4B33-904E-BF087FC2036AQ38945809-10C90F7F-7734-44EE-8196-35FE26BF9C51Q39003605-6AEF34FE-31DB-4532-A252-54B4320238D0Q39015916-13B80935-3E93-485F-8631-6DD66DC9B6CEQ40817871-A13E19C9-55CF-425C-8BE9-1312841F526FQ40989102-77EE1328-9608-4B02-ABA2-B8329E61A2B6Q42320319-C59E2A86-C64B-4246-A989-17CCFAF2B304Q44078054-7203912A-134E-416D-9DB0-649ADC2865DCQ46757995-42D13089-2266-4141-AFCA-D53B054134B5Q47137099-905E708A-3D53-453D-911C-DE5B18E9F50EQ47356155-28B6CEF8-3D40-464E-A9B6-397C39363BDDQ47692407-F26BF2A7-BD1B-4076-B5B5-1C1B3B4F0CADQ49320631-E253AB10-F4AA-40A4-BBDD-899E0F92DA1CQ49951711-7C5C0A72-9E69-4DEF-B317-4B4A54A9898AQ49964234-22392AD0-FA99-48BB-9525-69CA8CA8453DQ51550913-6C046BE0-AA95-43BA-905C-B7D2D2ABA39FQ53177700-4FE43A41-5F11-425C-8D41-C63DC33074EDQ54452516-6D09026B-D0C4-4E34-9014-E56F6237EC18Q55459972-956DF0F1-D503-4BA8-A589-51FD261ABCADQ55475614-466D32B1-0FEE-40D1-BF9A-4CDCC42B2D08Q55476432-0F3A664A-AB6A-414C-A658-E097F53616E5Q58542454-29A93D7E-192A-4AD1-AC6B-A180D430BCC2
P50
description
eesti biokeemik
@et
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Katrin Sak
@ast
Katrin Sak
@en
Katrin Sak
@es
Katrin Sak
@et
Katrin Sak
@nl
Katrin Sak
@sl
type
label
Katrin Sak
@ast
Katrin Sak
@en
Katrin Sak
@es
Katrin Sak
@et
Katrin Sak
@nl
Katrin Sak
@sl
prefLabel
Katrin Sak
@ast
Katrin Sak
@en
Katrin Sak
@es
Katrin Sak
@et
Katrin Sak
@nl
Katrin Sak
@sl
P106
P21
P2953
Katrin_Sak
P31
P496
0000-0003-0736-2525
P569
1975-01-01T00:00:00Z